REGENXBIO Inc. (RGNX)
RGNXNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$7.64
-0.3900 (-4.86%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $505.18m
- P/E
- –
- EPS, last 4 quarters
- $-3.21
- Dividend yield
- –
- Day range
- –
- 52-week range
- $5.46 to $16.19
- Average volume
- –
- Previous close
- $8.03
Analysts
11 coveringBuy9 buy, 2 hold, 0 sell
Targets a year out average $20.91, +173.7% from here
Earnings
next estimate $-1.26Next report
Dec 2025
-28.7%
Mar 2026
-26.5%
Jun 2026
+258.3%
Sep 2026
+54.1%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $30.34m | $6.39m | $108.02m | $9.16m |
| Gross profit | $24.41m | -$4.68m | $106.98m | $8.02m |
| Operating income | -$57.64m | -$83.36m | $29.26m | -$35.53m |
| Net income | -$67.15m | -$90.05m | $22.71m | -$40.74m |
Last four quarters: revenue $153.91m, margin -113.8%, free cash flow -$154.80m
News
8 latest- REGENXBIO Q3 Earnings Call HighlightsMarketBeat · Nov 6, 2026
- REGENXBIO Inc. Reports Third Quarter 2026 Financial Results and Program MilestonesFintel · Nov 5, 2026
- REGENXBIO (RGNX) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 5, 2026
- Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue EstimatesZacks · Nov 5, 2026
- Regenxbio Inc Q3 Loss Drops RTTNews · Nov 5, 2026
- Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?Zacks · Nov 4, 2026
- 4 Biotech Stocks Likely to Outpace Q3 Earnings EstimatesZacks · Nov 4, 2026
- AC Immune (ACIU) Reports Q3 Loss, Beats Revenue EstimatesZacks · Nov 4, 2026
The company
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and RGX-121 (clemidsogene lanparvovec) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA and ITVISMA. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- regenxbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.